Table of Contents

company-logo

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics Dividend Announcement

• Cognition Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Cognition Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Cognition Therapeutics Dividend History

Cognition Therapeutics Dividend Yield

Cognition Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cognition Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Cognition Therapeutics Financial Ratios

P/E ratio-0.65
PEG ratio0.02
P/B ratio0.88
ROE-118.11%
Payout ratio0.00%
Current ratio3.07
Quick ratio3.07
Cash Ratio2.61

Cognition Therapeutics Dividend FAQ

Does Cognition Therapeutics stock pay dividends?
Cognition Therapeutics does not currently pay dividends to its shareholders.
Has Cognition Therapeutics ever paid a dividend?
No, Cognition Therapeutics has no a history of paying dividends to its shareholders. Cognition Therapeutics is not known for its dividend payments.
Why doesn't Cognition Therapeutics pay dividends?
There are several potential reasons why Cognition Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Cognition Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Cognition Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Cognition Therapeutics a dividend aristocrat?
Cognition Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Cognition Therapeutics a dividend king?
Cognition Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Cognition Therapeutics a dividend stock?
No, Cognition Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Cognition Therapeutics stocks?
To buy Cognition Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Cognition Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.